Puma Biotechnology | PBYI - Selling And Administration Expenses


Puma Biotechnology reported $16.82M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Exelixis USD 123.02M 19.9M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
Incyte USD 390.41M 61.33M Dec/2025
MacroGenics USD 9.9M 600K Sep/2025
Moderna USD 308M 40M Dec/2025
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Takeda JPY 282.78B 29.23B Dec/2025
TG Therapeutics USD 50.73M 12.64M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025